Asset Details

MbrlCatalogueTitleDetail

Do you wish to reserve the book?

Survival with Osimertinib plus Chemotherapy in EGFR-Mutated Advanced NSCLC

by Jänne, Pasi A. , Valdiviezo, Natalia , Poltoratskiy, Artem , Lee, Chee Khoon , Neron, Yeni , Rukazenkov, Yuri , Biswas, Bivas , Mann, Helen , Armenteros-Monterroso, Elena , Planchard, David , Kim, Tae Min , Kagamu, Hiroshi , Wang, Jialei , Kobayashi, Kunihiko , Rojas, Carlos , Liu, Ying , Jiang, Liyan , Escriu, Carles , Yang, James Chih-Hsin , Ezeife, Doreen A. , Koubkova, Leona , Yanagitani, Noriko

in Acrylamides - administration & dosage / Acrylamides - adverse effects / Adult / Adverse events / Aged / Aged, 80 and over / Aniline Compounds - administration & dosage / Aniline Compounds - adverse effects / Antineoplastic Combined Chemotherapy Protocols - administration & dosage / Antineoplastic Combined Chemotherapy Protocols - adverse effects / Carboplatin / Carboplatin - administration & dosage / Carboplatin - adverse effects / Carcinoma, Non-Small-Cell Lung - drug therapy / Carcinoma, Non-Small-Cell Lung - genetics / Carcinoma, Non-Small-Cell Lung - mortality / Chemotherapy / Cisplatin / Cisplatin - administration & dosage / Cisplatin - adverse effects / Combination therapy / Critical Care / Critical Care General / Epidermal growth factor receptors / ErbB Receptors - antagonists & inhibitors / ErbB Receptors - genetics / Female / Gene deletion / Hematology / Humans / Indoles - administration & dosage / Indoles - adverse effects / Lung Cancer / Lung Neoplasms - drug therapy / Lung Neoplasms - genetics / Lung Neoplasms - mortality / Male / Middle Aged / Mutation / Non-small cell lung carcinoma / Oncology / Patients / Pemetrexed - administration & dosage / Pemetrexed - adverse effects / Platinum / Progression-Free Survival / Pulmonary / Pyrimidines - administration & dosage / Pyrimidines - adverse effects / Small cell lung carcinoma / Treatments in Oncology

2026

Yes Please

Hey, we have placed the reservation for you!

By the way, why not check out events that you can attend while you pick your title.

Oops! Something went wrong.

Looks like we were not able to place the reservation. Kindly try again later.

Are you sure you want to remove the book from the shelf?

Survival with Osimertinib plus Chemotherapy in EGFR-Mutated Advanced NSCLC

2026

Confirm

Do you wish to request the book?

Survival with Osimertinib plus Chemotherapy in EGFR-Mutated Advanced NSCLC

2026

Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy

How would you like to get it?

Submit

We have requested the book for you!

Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.

Oops! Something went wrong.

Looks like we were not able to place your request. Kindly try again later.

Journal Article

Survival with Osimertinib plus Chemotherapy in EGFR-Mutated Advanced NSCLC

Jänne, Pasi A.,

Valdiviezo, Natalia,

Poltoratskiy, Artem,

Lee, Chee Khoon,

Neron, Yeni,

Rukazenkov, Yuri,

Biswas, Bivas,

Mann, Helen,

Armenteros-Monterroso, Elena,

Planchard, David,

Kim, Tae Min,

Kagamu, Hiroshi,

Wang, Jialei,

Kobayashi, Kunihiko,

Rojas, Carlos,

Liu, Ying,

Jiang, Liyan,

Escriu, Carles,

Yang, James Chih-Hsin,

Ezeife, Doreen A.,

Koubkova, Leona,

Yanagitani, Noriko

2026

Overview

In EGFR -mutated non–small-cell lung cancer, first-line osimertinib plus platinum–pemetrexed extended overall survival to 47.5 months, as compared with 37.6 months with osimertinib alone, but increased the risk of adverse events.

Share this book

Add to My Shelf

Publisher

Massachusetts Medical Society

Subject

Acrylamides - administration & dosage

/ Acrylamides - adverse effects

/ Adult

/ Adverse events

/ Aged

/ Aged, 80 and over

/ Aniline Compounds - administration & dosage